Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Notes underwriting agrmnt
|
|
AXIM BIOTECHNOLOGIES, INC. (AXIM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 06/12/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/02/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 06/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 01/27/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/15/2022 |
10-Q/A
| Quarterly Report for the period ended September 30, 2022 [amend] |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/07/2022 |
144
| Form 144 - Report of proposed sale of securities: |
| 09/23/2022 |
4
| Schroeder Blake (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 1,000,000 options
@ $0.052, valued at
$52k
|
|
| 09/23/2022 |
3
| O'Rourke Peter (Director) has filed a Form 3 on AXIM BIOTECHNOLOGIES, INC. |
| 09/23/2022 |
4
| MALASEK ROBERT (CFO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 500,000 options
@ $0.052, valued at
$26k
|
|
| 09/23/2022 |
4
| MALASEK ROBERT (CFO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 300,000 options
@ $0.42, valued at
$126k
|
|
| 09/23/2022 |
4
| Cunningham Robert L (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 1,000,000 options
@ $0.052, valued at
$52k
|
|
| 09/23/2022 |
4
| Cunningham Robert L (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 500,000 options
@ $0.0126, valued at
$6.3k
|
|
| 09/23/2022 |
4
| Scott Timothy Richard (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 1,000,000 options
@ $0.052, valued at
$52k
|
|
| 09/23/2022 |
4
| Scott Timothy Richard (Director) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 500,000 options
@ $0.0126, valued at
$6.3k
|
|
| 09/23/2022 |
4
| HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 5,000,000 options
@ $0.052, valued at
$260k
|
|
| 09/23/2022 |
4
| HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Disposed/sold 2,000,000 options
@ $0.75, valued at
$1.5M
|
|
| 09/23/2022 |
4
| HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 3,000,000 options
@ $0.42, valued at
$1.3M
|
|
| 09/23/2022 |
4
| HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Bought 6,000,000 shares
@ $0 |
|
| 09/23/2022 |
4
| HUEMOELLER JOHN WALTER II (CEO) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Granted 2,000,000 options
@ $0.75, valued at
$1.5M
|
|
| 09/23/2022 |
SC 13D
| Juniper & Ivy Corp reports a 100% stake in AXIM Biotechnologies, Inc. |
| 09/23/2022 |
3
| Juniper & Ivy Corp (10% Owner) has filed a Form 3 on AXIM BIOTECHNOLOGIES, INC. |
| 09/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"September 15, 2022, License and Distribution Agreement by and between AXIM Biotechnologies, Inc. and Verséa Ophthalmics, LLC [Portions have been omitted]",
"About AXIM® Biotechnologies Founded in 2014, AXIM® Biotechnologies, Inc. is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com . About Verséa Holdings, Inc. Verséa Holdings, Inc. headquartered in Tampa, FL, is a U.S. healthcare company founded by experienced business executives and prominent scientific medical experts with a combined 350+ years of experience, all committed to transforming scientific discoveries into applicable healthcare & wellness solutions that are critical to improving patients’ lives. ..." |
|
| 08/31/2022 |
SC 13D/A
| Valencia Catalina reports a 12.9% stake in AXIM Biotechnologies, Inc. |
| 08/31/2022 |
4
| Valencia Catalina (10% Owner) has filed a Form 4 on AXIM BIOTECHNOLOGIES, INC.|
Txns:
| Bought 3,861,004 shares
@ $0.0259, valued at
$100k
|
|
| 08/31/2022 |
SC 13D
| Glycodots, LLC reports a 14.3% stake in AXIM Biotechnologies, Inc. |
| 08/31/2022 |
3
| Glycodots, LLC (10% Owner) has filed a Form 3 on AXIM BIOTECHNOLOGIES, INC. |
| 08/31/2022 |
SC 13D
| Valencia Catalina reports a 14.3% stake in AXIM Biotechnologies, Inc. |
| 08/31/2022 |
3
| Valencia Catalina (10% Owner) has filed a Form 3 on AXIM BIOTECHNOLOGIES, INC. |
|
|
|